# Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

> **NCT06838910** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Thymic Carcinoma
- Thymoma

## Interventions

- **DRUG:** Experimental: tislelizumab+anlotinib

## Key facts

- **NCT ID:** NCT06838910
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2026-12
- **Final completion:** 2026-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838910, "Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06838910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*